JP6585167B2 - Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 - Google Patents

Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 Download PDF

Info

Publication number
JP6585167B2
JP6585167B2 JP2017517705A JP2017517705A JP6585167B2 JP 6585167 B2 JP6585167 B2 JP 6585167B2 JP 2017517705 A JP2017517705 A JP 2017517705A JP 2017517705 A JP2017517705 A JP 2017517705A JP 6585167 B2 JP6585167 B2 JP 6585167B2
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
hydroxy
substituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017517705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530154A (ja
JP2017530154A5 (cg-RX-API-DMAC7.html
Inventor
フェアハースト，ロビン，アレク
フュレ，パスカル
ノップフェル，トーマス
ルブラン，キャサリン
リャオ，エルブイ
マー，ロバート
ニムズガーン，ピエール
リポシュ，セバスチャン
ション，ジン
ツァオ，シャンリン
ハン，ボ
ワン，キャン
ポーター，デール
ブッシュマン，ニコール
ポータ，ダイアナ グラウス
ポータ，ダイアナ グラウス
ヘフリガー，キャロリナ
村上　雅人
雅人 村上
パルマー，マイケル
ワン，ヨウツェン
ワイス，アンドレアス
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017530154A publication Critical patent/JP2017530154A/ja
Publication of JP2017530154A5 publication Critical patent/JP2017530154A5/ja
Application granted granted Critical
Publication of JP6585167B2 publication Critical patent/JP6585167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017517705A 2014-10-03 2015-10-02 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 Active JP6585167B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014088094 2014-10-03
CNPCT/CN2014/088094 2014-10-03
PCT/US2015/053677 WO2016054483A1 (en) 2014-10-03 2015-10-02 Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019161051A Division JP6794514B2 (ja) 2014-10-03 2019-09-04 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Publications (3)

Publication Number Publication Date
JP2017530154A JP2017530154A (ja) 2017-10-12
JP2017530154A5 JP2017530154A5 (cg-RX-API-DMAC7.html) 2018-11-15
JP6585167B2 true JP6585167B2 (ja) 2019-10-02

Family

ID=54330059

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017517705A Active JP6585167B2 (ja) 2014-10-03 2015-10-02 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
JP2019161051A Active JP6794514B2 (ja) 2014-10-03 2019-09-04 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019161051A Active JP6794514B2 (ja) 2014-10-03 2019-09-04 Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Country Status (6)

Country Link
US (3) US20180185341A1 (cg-RX-API-DMAC7.html)
EP (1) EP3200786B1 (cg-RX-API-DMAC7.html)
JP (2) JP6585167B2 (cg-RX-API-DMAC7.html)
ES (1) ES2756748T3 (cg-RX-API-DMAC7.html)
PL (1) PL3200786T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016054483A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019218398A (ja) * 2014-10-03 2019-12-26 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7103952B2 (ja) * 2016-05-20 2022-07-20 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 Ｆｇｆｒ４阻害剤、その製造方法及び応用
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
CN117257800A (zh) * 2016-11-02 2023-12-22 诺华股份有限公司 Fgfr4抑制剂和胆汁酸螯合剂的组合
TWI723480B (zh) * 2018-07-27 2021-04-01 大陸商北京加科思新藥研發有限公司 用作fgfr4抑制劑的稠環衍生物
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
US6140338A (en) 1996-07-29 2000-10-31 Banyu Pharmaceutical, Co., Ltd. Chemokine receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
CO4980854A1 (es) 1998-02-10 2000-11-27 Novartis Ag Inhibidores de celulas b particularmente amidas, proceso par su produccion y composiciones farmaceuticas que los contiene
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
WO2001034602A2 (en) * 1999-11-08 2001-05-17 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
JPWO2003068753A1 (ja) 2002-02-14 2005-06-02 小野薬品工業株式会社 Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
MXPA05001536A (es) * 2002-08-30 2005-04-19 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
CA2510851A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
AU2004229404B2 (en) 2003-04-11 2008-01-10 Taigen Biotechnology Aminoquinoline compounds
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
BRPI0613045A2 (pt) 2005-07-15 2010-12-14 Hoffmann La Roche aminas cÍclicas fundidas a heteroarila
US20070129364A1 (en) * 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
BRPI0620408B8 (pt) * 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
CN101405002A (zh) 2005-12-29 2009-04-08 詹森药业有限公司 激肽原2受体拮抗剂
EP1989230B1 (en) 2006-02-10 2016-06-01 Genentech, Inc. Anti-fgf19 antibodies and methods using same
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007141473A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
KR20090119768A (ko) 2007-03-09 2009-11-19 노파르티스 아게 흑색종 치료법
SI2550972T1 (en) 2007-04-02 2018-05-31 Genentech, Inc. An antibody called Klotho-beta agonist for use in the treatment of diabetes mellitus or insulin resistance
JP2011507848A (ja) 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのベンゾピランおよびアナログ
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
JP2012501637A (ja) 2008-09-03 2012-01-26 ライセンティア・リミテッド Ｆｇｆｒ４に関連する癌細胞浸潤を抑制するための材料および方法
WO2010027002A1 (ja) 2008-09-05 2010-03-11 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
BRPI0918337A2 (pt) 2008-12-19 2017-05-30 Abbott Lab composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso
GB0906470D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
WO2010129467A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
JP2013509442A (ja) 2009-10-29 2013-03-14 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節因子としての二環式ピリジンおよび類似体
KR20120101367A (ko) 2009-10-30 2012-09-13 노파르티스 아게 3-（2,6-디클로로-3,5-디메톡시-페닐）-1-｛6-［4-（4-에틸-피페라진-1-일）-페닐아미노］-피리미딘-4-일｝-1-메틸-우레아의 ｎ-옥시드
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
WO2012061337A1 (en) * 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
AU2012232706B2 (en) 2011-03-18 2016-12-15 Lupin Atlantis Holdings Sa Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
WO2012138975A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
CN109627239B (zh) 2012-07-11 2021-10-12 缆图药品公司 成纤维细胞生长因子受体的抑制剂
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US20150290235A1 (en) 2012-11-23 2015-10-15 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
EA036160B1 (ru) 2013-03-15 2020-10-08 Селджен Кар Ллс Гетероарильные соединения и их применение
ME03015B (me) 2013-04-19 2018-10-20 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CA2917667A1 (en) 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
PH12016500676B1 (en) 2013-10-18 2022-07-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
PH12016500739B1 (en) 2013-10-25 2022-04-29 Blueprint Medicines Corp Inhibitors of the fibrolast growth factor receptor
PE20160546A1 (es) * 2013-10-25 2016-05-26 Novartis Ag Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
PL3200786T3 (pl) * 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3273959A1 (en) * 2015-03-25 2018-01-31 Novartis Ag Pharmaceutical combinations
CN117257800A (zh) 2016-11-02 2023-12-22 诺华股份有限公司 Fgfr4抑制剂和胆汁酸螯合剂的组合

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019218398A (ja) * 2014-10-03 2019-12-26 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用

Also Published As

Publication number Publication date
PL3200786T3 (pl) 2020-03-31
JP2017530154A (ja) 2017-10-12
JP2019218398A (ja) 2019-12-26
US20190076412A1 (en) 2019-03-14
EP3200786A1 (en) 2017-08-09
WO2016054483A1 (en) 2016-04-07
EP3200786B1 (en) 2019-08-28
ES2756748T3 (es) 2020-04-27
US20180185341A1 (en) 2018-07-05
US20190231760A1 (en) 2019-08-01
US10507201B2 (en) 2019-12-17
JP6794514B2 (ja) 2020-12-02
US10463653B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
JP6585167B2 (ja) Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
JP6745856B2 (ja) Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体
CN101945869B (zh) 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
EP2947081B1 (en) 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors
EP4441055A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250129096A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP4926973B2 (ja) 治療化合物としての、イミダゾ［４，５−ｂ］ピリジン−２−オンおよびオキサゾロ［４，５−ｂ］ピリジン−２−オン化合物ならびにそれらの類似体
WO2022061251A1 (en) Compounds and methods for kras modulation and indications therefor
RS59110B1 (sr) Heteroarilni sik inhibitori
JP2011513483A (ja) タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
CN102066371A (zh) 芳基-喹啉基化合物及其用途
JP2022526364A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP7339263B2 (ja) Ｊａｋ阻害剤としてのピラゾロピリミジン化合物
JP2022526176A (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
TWI690528B (zh) 稠環雙環吡啶基衍生物
HK1222388B (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
HK1174038A (en) 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190904

R150 Certificate of patent or registration of utility model

Ref document number: 6585167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250